Journal
BLOOD REVIEWS
Volume 30, Issue 6, Pages 477-491Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2016.06.003
Keywords
Diffuse large B cell lymphoma (DLBCL); Chemotherapy; Autologous stem cell transplant; Novel targeted therapy for lymphoma
Categories
Funding
- Pharmacyclics
- Celgene
- Genentech
Ask authors/readers for more resources
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of lymphoma. We now recognize that DLBCL corresponds to a biologically heterogeneous family of diseases. Given the potential for cure for most DLBCL patients, appropriate diagnostic and staging evaluation and therapy are essential. Here we review areas of consensus as well as controversy in the evaluation, treatment and monitoring of patients with DLBCL and its related subtypes. (C) 2016 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
